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We feel that such an approach is worth being further investigated We describe a young white female with long-lasting systemic in patients with life-threatening autoimmune disorders not relupus erythematosus (SLE) and subsequent chronic myelogenous sponding or badly responding to conventional immunosuppressive leukemia (CML) undergoing unmanipulated ABMT after the onset therapy, offering a chance of reduction in long-term steroid treatment and therapeutic remission of blastic crisis. ABMT was followed by morbidity and perhaps a better quality of life. 
